Golden jubilee of hypertrophic cardiomyopathy: is alcohol septal ablation the gold standard?

Cardiovascular Revascularization Medicine

Volumn 10, Issue 3, 2009, Pages 172-178

  Parakh, Neeraj ^a   Bhargava, Balram ^b  

^a G B PANT HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Alcohol septal ablation; Hypertrophic obstructive cardiomyopathy

Indexed keywords

ALCOHOL SEPTAL ABLATION; ANGIOCARDIOGRAPHY; CARDIAC PATIENT; CATHETER ABLATION; COMPLETE HEART BLOCK; FEMORAL ARTERY; GOLD STANDARD; HEART LEFT BUNDLE BRANCH BLOCK; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ETHANOL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PATIENT SATISFACTION; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 67649990803     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2009.02.006     Document Type: Review

References (75)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 20 (1958) 1-8
2. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346 (1995) 211-214
3. Sigwart U. Catheter treatment for hypertrophic obstructive cardiomyopathy: for seniors only?. Circulation 118 (2008) 107-108
4. Maron B.J., and Salberg L. Historical perspective and names. In: Maron B.J., and Salberg L. (Eds). Hypertrophic cardiomyopathy: for patients, their families and interested physicians (2007), Blackwell- Synergy publications, Minneapolis, MN 1-4
5. Sigwart U., Grbic M., Payot M., Essinger A., and Sadeghi H. Ventricular wall motion during balloon occlusion. In: Sigwart U., and Heintzen P.H. (Eds). Ventricular wall motion (1983), George Theime, New York (NY) 206-210
6. Come P.C., and Riley M.F. Hypertrophic cardiomyopathy, disappearance of auscultatory, carotid pulse, and echocardiographic manifestation of obstruction following myocardial infarction. Chest 82 (1982) 451-454
7. Waller B.F., Maron B.J., Epstein S.E., and Roberts W.C. Transmural myocardial infarction in hypertrophic cardiomyopathy: a cause of conversion from left ventricular asymmetry and from normal-size to dilated left ventricular cavity. Chest 79 (1981) 461-465
8. Angelini P. The "first septal unit" in hypertrophic obstructive cardiomyopathy. Tex Heart Inst J 34 (2007) 336-346
9. Sahni D., and Jit I. Blood supply of the human interventricular septum in north-west Indians [published erratum appears in Indian Heart J 1990;42:334]. Indian Heart J 42 (1990) 161-169
10. Angelini P., Villason S., Chan A.V., and Diez J.G. Normal and anomalous coronary arteries in humans. In: Angelini P. (Ed). Coronary artery anomalies: a comprehensive approach (1999), Lippincott Williams & Wilkins, Baltimore 27-150
11. Hosseinpour A.R., Anderson R.H., and Ho S.Y. The anatomy of the septal perforating arteries in normal and congenitally malformed hearts. J Thorac Cardiovasc Surg 121 (2001) 1046-1052
12. Singh M., Edwards W.D., Holmes D.R., Tajil A.J., and Nishimura R.A. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 76 (2001) 799-802
13. Said M., and Muhlberger V.A. The descending septal branch (Bonapace's branch). A case report and literature review of this often forgotten branch. First description in vivo. Eur Heart J 16 (1995) 1443-1447
14. Qin J.X., Shiota T., Lever H.M., Asher C.R., Popović Z.B., Greenberg N.L., Agler D.A., Drinko J.K., Smedira N.G., Tuzcu E.M., Lytle B.W., and Thomas J.D. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 93 (2004) 171-175
15. Chang S.M., Nagueh S.F., Spencer W.H., and Lakkis N.M. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 42 (2003) 296-300
16. Chen A.A., Palacios I.F., Mela T., Yoerger D.M., Picard M.H., Vlahakes G., Lowry P.A., and Fifer M.A. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97 (2006) 264-269
17. van den Brandhof G., and Zijlstra F. Separate origin of a large septal perforator branch. Cathet Cardiovasc Diagn 25 2 (1992) 151-153
18. Rath S., Har-Zahav Y., Battler A., Agranat O., Schneeweiss A., Rabinowitz B., and Neufeld H.N. Frequency and clinical significance of anomalous origin of septal perforator coronary artery. Am J Cardiol 58 7 (1986) 657-658
19. Maron B.J., McKenna W.J., Danielson G.K., Kappenberger L.J., Kuhn H.J., Seidman C.E., Shah P.M., Spencer W.H., Spirito P., Ten Cate F.J., Wigle E.D., American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, and European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24 (2003) 1965-1991
20. Seggewiss H. Medical therapy versus interventional therapy in hypertrophic obstructive cardiomyopathy. Curr Control Trials Cardiovasc Med 1 (2000) 115-119
21. Lakkis N.M., Plana J.C., Nagueh S., Killip D., Roberts R., and Spencer W.H. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol 88 (2001) 583-586
22. Sigwart U. Catheter-based septal ablation for patients with hypertrophic cardiomyopathy. In: Bertand M.E. (Ed). The Evolution of Cardiac Catheterization and Interventional Cardiology (2006), Iatric Press and The European society of cardiology, St Albans 207-217
23. Seggwiss H., Faber L., Meyners W., Bogunovic N., Odenthal H.J., and Gleichmann U. Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report. Cathet Cardiovasc Diagn 44 (1998) 65-69
24. Bhargava B., Agarwal R., Kaul U., Manchanda S.C., and Wasir H.S. Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Diagn 41 1 (1997) 56-58
25. Bhargava B., Agarwal R., Kaul U., Manchanda S.C., and Wasir H.S. Transcatheter alcohol ablation of the septum in hypertrophic cardiomyopathy. Tex Heart Inst J 25 (1998) 156-157
26. Faber L., Seggewiss H., Welge D., Fassbender D., Schmidt H.K., Gleichmann U., and Horstkotte D. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 5 (2004) 347-355
27. Lakkis N.M., Nagueh S.F., Kleiman N.S., Killip D., He Z.X., Verani M.S., Roberts R., and Spencer W.H. Echocardiography guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98 (1998) 1750-1755
28. Nagueh S.F., Lakkis N.M., He Z.X., Middleton K.J., Killip D., Zoghbi W.A., Quiñones M.A., Roberts R., Verani M.S., Kleiman N.S., and Spencer W.H. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 32 (1998) 225-229
29. Faber L., Seggewiss H., and Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98 (1998) 2415-2421
30. Pedone C., Vijayakumar M., Ligthart J.M., Valgimigli M., Biagini E., Jong N.D., Serruys P.W., and Ten Cate F.J. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy. Int J Cardiovas Interv 7 (2005) 134-137
31. Veselka J., Duchonová R., Procházková S., Pálenícková J., Sorajja P., and Tesar D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 95 (2005) 675-678
32. Baggish A.L., Smith R.N., Palacios I., Vlahakes G.J., Yoerger D.M., Picard M.H., Lowry P.A., Jang I.K., and Fifer M.A. Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 92 (2006) 1773-1778
33. Aqel R.A., Hage F.G., Zohgbi G.J., Tabereaux P.B., Lawson D., Heo J., Perry G., Epstein A.E., Dell' Italia L.J., and Iskandrian A.E. Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients. Am J Cardiol. 101 9 (2008) 1328-1333
34. van Dockum W.G., Kuijer J.P., Götte M.J., Ten Cate F.J., Ten Berg J.M., Beek A.M., Twisk J.W., Marcus J.T., Visser C.A., and van Rossum A.C. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J 27 23 (2006) 2833-2839
35. Soliman O., Geleijnse M.L., Michels M., Dijkmans P.A., Nemes A., van Dalen B.M., Vletter W.B., Serruys P.W., and ten Cate F.J. Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 101 (2008) 1321-1327
36. Smith E., Anthony R., Mo R., Jain A., Preston M., McConnell K., Macey M., Rothman M., Mathur A., and Knight C. Myocardial infarction induced by alcohol septal ablation for hypertrophic cardiomyopathy does not activate platelets. Heart 92 Suppl 2 (2006) A96-A97
37. Veselka J., Duchonova R., Prochazkova S., Homolova I., Páleníckova J., Zemanek D., Pernisova Z., and Tesar D. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol 60 (2004) 133-137
38. Yoerger D.M., Picard M.H., Palacios I.F., Vlahakes G.J., Lowry P.A., and Fifer M.A. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97 (2006) 1511-1514
39. Lakkis N.M., Nagueh S.F., Dunn J.K., Killip D., and Spencer W.H. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36 (2000) 852-855
40. Airoldi F., Di Mario C., Catanoso A., Dharmadhikari A., Tzifos V., Anzuini A., Carlino M., Briguori C., Montorfano M., Vaghetti M., Tolaro S., and Colombo A. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 1 (2000) 200-206
41. Carasso S., Woo A., Yang H., Schwartz L., Vannan M.A., Jamorski M., Linghorne M., Wigle E.D., and Rakowski H. Myocardial mechanics explains the time course of benefit for septal ethanol ablation for hypertrophic cardiomyopathy. J Am Soc Echocardiogr 21 5 (2008) 493-499
42. Steendijk P., Meliga E., Valgimigli M., Ten Cate F.J., and Serruys P.W. Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart 94 (2008) 1318-1322
43. Sitges M., Shiota T., Lever H.M., Qin J.X., Bauer F., Drinko J.K., Agler D.A., Martin M.G., Greenberg N.L., Smedira N.G., Lytle B.W., Tuzcu E.M., Garcia M.J., and Thomas J.D. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 91 (2003) 817-821
44. Meliga E., Steendijk P., Valgimigli M., Ten Cate F.J., and Serruys P.W. Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic cardiomyopathy on systolic and diastolic left ventricular function assessed by pressure-volume loops. Am J Cardiol. 101 8 (2008) 1179-1184
45. Jassal D.S., Neilan T.G., Fifer M.A., Palacios I.F., Lowry P.A., Vlahakes G.J., Picard M.H., and Yoerger D.M. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J 27 (2006) 1805-1810
46. Alam M., Dokainish H., and Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interven Cardiol 19 (2006) 319-327
47. Hage F.G., Karakus G., Luke Jr. W.D., Suwanjutah T., Nanda N.C., and Aqel R.A. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional transthoracic echocardiography in patients with hypertrophic cardiomyopathy. Echocardiography 25 (2008) 784-789
48. Henein M.Y., O'Sullivsn C.A., Ramzy I.S., Sigwart U., and Gibson D.G. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 34 (1999) 1117-1122
49. Runquist L.H., Nielsen C.D., Killip D., Gazes P., and Spencer W.H. Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 90 (2002) 1020-1022
50. Kwon D.H., Kapadia S.R., Tuzcu E.M., Halley C.M., Gorodeski E.Z., Curtin R.J., Thamilarasan M., Smedira N.G., Lytle B.W., Lever H.M., and Desai M.Y. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. J Am Coll Cardiol Intv 1 4 (2008) 432-438
51. Chowdhary S., Galiwango P., Woo A., and Schwartz L. Inferior infarction following alcohol septal ablation: a consequence of "collateral damage"?. Catheter Cardiovasc Interv 69 2 (2007) 236-242
52. Aroney C.N., Goh T.H., Hourigan L.A., and Dyer W. Ventricular septal rupture following nonsurgical septal reduction for hypertrophic cardiomyopathy: treatment with percutaneous closure. Catheter Cardiovasc Interv 61 (2004) 411-414
53. Faber L., Welge D., Fassbender D., Schmidt H.K., Horstkotte D., and Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 119 2 (2007) 163-167
54. van der Lee C., Scholzel B., ten Berg J.M., Geleijnse M.L., Idzerda H.H., van Domburg R.T., Vletter W.B., Serruys P.W., and ten Cate F.J. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 101 9 (2008) 1315-1320
55. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 21 (2000) 704-747
56. Boekstegers P., Steinbigler P., Molnar A Schwaiblmair M., Becker A., Knez A., Haberl R., and Steinbeck G. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38 (2001) 846-853
57. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH) in HOCM: a five-year experience. Z Kardiol 89 (2000) 559-564
58. Li Z.Q., Cheng T.O., Liu L Jin Y.Z., Zhang M., Guan R.M., Yuan L., Hu J., and Zhang W.W. Experimental study of relationship between intracoronary alcohol injection and the size of resultant myocardial infarct. Int J Cardiol 91 1 (2003) 93-96
59. Bhargava B., and Agarwal R. Can we predict complete heart block after alcohol ablation for hypertrophic cardiomyopathy?. Circulation 100 25 (1999) e144
60. McGregor J.B., Rahman A., Rosanio S., Ware D., Birnbaum Y., and Saeed M. Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci 328 3 (2004) 185-188
61. Lawrenz T., Obergassel L., Lieder F Leuner C., Strunk-Mueller C., Meyer Zu Vilsendorf D., Beer G., and Kuhn H. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 28 (2005) 295-300
62. Qin J.X., Shiota T., Lever HM Kapadia S.R., Sitges M., Rubin D.N., Bauer F., Greenberg N.L., Agler D.A., Drinko J.K., Martin M., Tuzcu E.M., Smedira N.G., Lytle B., and Thomas J.D. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38 (2001) 1994-2000
63. Nagueh S.F., Ommen S.R., Lakkis NM Killip D., Zoghbi W.A., Schaff H.V., Danielson G.K., Quiñones M.A., Tajik A.J., and Spencer W.H. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38 (2001) 1701-1706
64. Ralph-Edwards A., Woo A., McCrindle BW Shapero J.L., Schwartz L., Rakowski H., Wigle E.D., and Williams W.G. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 129 (2005) 351-358
65. Firoozi S., Elliott P.M., Sharma S., Murday A., Brecker S.J., Hamid M.S., Sachdev B., Thaman R., and McKenna W.J. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 23 (2002) 1617-1624
66. Sorajja P., Valeti U., Nishimura RA Ommen S.R., Rihal C.S., Gersh B.J., Hodge D.O., Schaff H.V., and Holmes Jr. D.R. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 118 (2008) 131-139
67. Maron B.J. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 116 (2007) 196-206
68. Fifer M.A. Most fully informed patients choose septal ablation over septal myectomy. Circulation 116 (2007) 207-216
69. Durand E., Mousseaux E., Coste P., Pillière R., Dubourg O., Trinquart L., Chatellier G., Hagège A., Desnos M., and Lafont A. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J 29 3 (2008) 348-355
70. Gross C.M., Schulz-Menger J., Krämer J., Siegel I., Pilz B., Waigand J., Friedrich M.G., Uhlich F., and Dietz R. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes. J Endovasc Ther. 11 6 (2004) 705-711
71. Trehan V., Mukhopadhyay S., and Rangasetty U.C. Percutaneous transseptal myocardial ablation with wire (PTSAW): a new technique. J Invasive Cardiol 16 4 (2004) 204-206
72. Oto A., Aytemir K., and Deniz A. New approach to septal ablation: glue (cyanoacrylate) septal ablation. Catheter Cardiovasc Interv 69 7 (2007) 1021-1025
73. Llamas-Esperón G.A., and Sandoval-Navarrete S. Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv 69 2 (2007) 231-235
74. Emmel M., Sreeram N., deGiovanni J.V., and Brockmeier K. Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Z Kardiol 94 10 (2005) 699-703
75. Math R.S., Singh S., Seth S Shankar B., Bhargava B., Sharma S., and Gulati G. Delayed response following trans-catheter coil embolization in HOCM. Indian Heart J 59 4 (2007) 383-385